

JOSH SHIN

Partner, Fangda Partners

+86 21 22081109
jshin@fangdalaw.com



PRACTICE AREAS

MR. JOSH SHIN SPECIALIZES IN M&A, PRIVATE EQUITY INVESTMENT, AND OVERSEAS CAPITAL MARKETS, WITH AN UNPARALLELED TRACK RECORD IN VARIOUS INDUSTRY SECTORS SUCH AS PHARMA, LIFE SCIENCE, HEALTHCARE, PRIVATE EDUCATION AND GENERAL INDUSTRY.

REPRESENTATIVE MATTERS AND CASES

Merger and Acquisition, Investment and General Corporate:

- Representing **Covestro AG** in acquiring a leading thin film company in Guangdong Province.
- Representing **Bayer Healthcare China** in selling its TCM products and manufacturing plant to a leading Chinese pharmaceutical company.
- Representing **Everbright Holdings** in its investment in Shenzhen Lifetech (01302.HK), the leading supplier of minimally invasive interventional medical devices to treat cardiovascular diseases.
- Representing **EddingPharm** in Series E/F financings.
- Representing **AnHeart Therapeutics** in daily operation and equity financing.
- Representing **Eddingpharm** in its US\$375 million acquisition from **Eli Lilly** of the rights for two legacy antibiotic medicines in China, Ceclor and Vancocin, as well as a manufacturing facility in Suzhou that produces Ceclor.
- Representing **Bayer HealthCare China** in the reorganization of its corporate structure to integrate with the onshore part of **Merck OTC Business**, following Bayer's global acquisition of Merck OTC department.
- Representing **Bayer AG** in its acquisition of 100% interest in **Dihon Pharmaceutical Group**, a leading OTC and traditional Chinese medicine company in China (CBLJ Deal of the Year).
- Representing the **The Ritedose Corporation**, a US-based, world-class BFS manufacturing company, in its joint venture with **Humanwell**.
- Representing **Wuxi AppTec** in forming a joint venture with **Mayo Clinic** regarding advanced medical examination technologies.
- Representing **E-Shang Redwood** in its series of acquisitions of logistic assets in China.

- Representing **LOGOS** in its acquisition of logistic assets in China.
- Representing **Education Index Management** (the owner of **Dulwich College International**) in its various rounds of private equity financing.
- Advising **Dulwich College International** China schools and **Dehong Chinese International School** on various legal issues in their daily operations, including new school openings, campus construction and expansion, regulatory compliance, related-party transactions, procurement, data protection, school management and debt financing.
- Advising partners of **Alibaba** in establishing **Yungu School**.
- Advising **Shanghai Concord Bilingual School** in its corporate restructuring, campus expansion and daily operation.
- Advising **British Education** (running **Wycombe Abby** China schools) in its private equity financing as well as operational matters.
- Representing a PE investor in its Series-A investment in a K-12 bilingual school.
- Representing a USD fund in its proposed investment in **NIT Education**.
- Representing **World Strides**, the largest educational travel company in the world, in acquiring a summer camp business in China.
- Representing the buyers group led by the founder in its attempted taking private of **iKang Healthcare Group Inc.**
- Representing **Olympus Capital** in its pre-IPO investment into a China private hospital group.
- Representing **Parkway Health**, a leading healthcare services provider in Asia, in its investment into several private hospitals and clinics in various provinces in China.
- Representing **Celanese** in various asset disposal projects and in daily operation matters.
- Representing a **leading healthcare services provider** in Asia in its attempted investment into a physical examination company based in Shanghai and in setting up a joint venture engaging in primary care clinics.
- Representing **PAG** in bidding for **Cardinal Health**'s China business.
- Representing the buyers group led by the founder and **TPG** in its taking private of **ShangPharma Corporation**, a leading China-based CRO company.
- Representing **Mount Kellett** (now **Fortress Investment**) in its series equity investments in China.
- Representing **Cargotec** in its establishment of a joint venture for major logistics and construction equipment with **SinoTruk**.
- Representing **CBI China**, a leading China-based bulk commodity information company, and its founders in selling its information business to **Reed Elsevier**.
- Representing various foreign investors, such as **Vale Inco**, **Tyson**, **MiaSolé** and **Bullen Ultrasonic**, in their disposal of PRC businesses.

Regulatory work:

- Representing **Assembly BioSciences**, an innovative US drug company listed on the NASDAQ, in establishing its China business.
- Representing **C-Stone Pharmaceuticals**, **AnHeart Therapeutics**, **Biogen**, **Astellas Pharma** and **Assembly BioSciences** in their R&D projects and clinical trials.
- Representing **Novartis AG**, **Roche Pharmaceuticals**, **AstraZeneca**, **C-Stone Pharmaceuticals**, **Biogen**, **Bayer Healthcare**, **Carl Zeiss** and a number of other life science companies in regulatory issues arising from daily business,

including market authorization, product distribution, PAP/PSP, PBM, product promotion, and NGO/PAG interactions.

Product Licensing and collaboration:

- Representing a **leading innovative pharmaceutical company** in its proposed grant of exclusive commercialization rights for its pipeline PD-L1 monoclonal antibody to a leading pharmaceutical commercial company.
- Representing **C-Stone Pharmaceuticals** in its obtaining a global license from **WuXi Biologics** for PD-L1/TGF β bifunctional molecule.
- Represented **C-Stone Pharmaceuticals** in its collaboration with **Zelgen** on combined therapy study of compounds from two parties.
- Representing **Harbour BioMed** in its collaboration with **Kelun-Biotech** to develop fully human therapeutic monoclonal antibodies based on Harbour's patented H2L2 transgenic mouse platform.
- Representing **AstraZeneca** in obtaining the exclusive promotion rights Luye Pharmaceuticals to Xue Zhi Kang Capsule, a first-line blood lipid management drug. This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company.
- Representing **AstraZeneca** in its granting of certain rights in China relating to a key originator drug to a leading domestic pharma company.
- Representing **Novartis** in its granting of exclusive promotion rights for certain respiratory drugs in China to a leading domestic pharma company.
- Representing **AstraZeneca** in its granting of exclusive commercialization rights for Plendil in the China market to **China Medical System** for an upfront fee of USD 310 million and an ongoing economic sharing arrangement.
- Representing **AstraZeneca** in its granting of exclusive commercialization rights for certain GLP-1 diabetes drugs in the China market to **3Sbio** for an upfront fee of USD 100 million and an ongoing economic sharing arrangement.
- Representing **AstraZeneca**, from the PRC legal perspective, on its global disposal of its anaesthetic business to **ASPEN**.
- Advising **EddingPharm** in its acquisition of assets related to drug products from two global pharmaceutical companies.

Capital Market:

- Advising on bond offering transactions for a number of issuers and underwriters, including **GCL Poly**, **Biostime** and **Asia Standards**.
- Advising issuers and underwriters in a number of initial public offerings and other capital market transactions, including **Chi-Med's** NASDAQ follow-on offering, **C-Stone Pharmaceuticals' HKSE IPO**, **Zai Lab's** NASDAQ IPO, **Wuxi Biologics' HKSE IPO**, **Simcom's** HKSE IPO, **Ruici Health's** HKSE IPO, **Trina Solar's** NASDAQ IPO and follow on offering, **Montage Technology's** NASDAQ IPO, **ShangPharma's** NYSE IPO, and **China iKang's** NYSE IPO.

Accolades

- Recommended as leading lawyer for healthcare by **Chambers and Partners** – Asia Pacific 2019 and 2020.
- Recommended as leading individual for “healthcare and life-science” by **Legal 500** – Asia Pacific 2020.

Education

- University College London (UCL), Faculty of Law, LL.M
- Fudan University, School of Law, LL.B.

Professional Qualification

- Admitted to practice in the PRC

Presentation/Publication

- Panel speaker “From Clinics to Sales – the Pathway and Challenge of Commercialization of Innovative Life Science Company” Wuxi AppTec Healthcare Forum (2019 Shanghai)
- Panel speaker “New Competition Dynamic Brought by Medical Reform” AstraZeneca Annual Conference (2018 Chengdu)
- Speaker “Recent Regulatory Development in Pharmaceutical Distribution” CCPIT Compliance Conference (2018 Shanghai)
- Panel speaker “Compliance Hot Issues in Pharma Area” CCPIT Compliance Conference (2018 Beijing)
- Panel speaker “Recent Trend in Healthcare M&A” IBA Hong Kong Asia Pacific M&A Conference (2017 Hong Kong)
- Lead Author “Pharma Legal Handbook - PRC” published by Pharma Boardroom.